--- title: Jack Schuler Kept Buying QuidelOrtho Below $12 as the Diagnostics Story Was Still Being Rebuilt type: news slug: jack-schuler-kept-buying-quidelortho-below-12-while-the-stock-was-still-rebuilding canonical_url: https://13finsight.com/news/jack-schuler-kept-buying-quidelortho-below-12-while-the-stock-was-still-rebuilding published_at: 2026-03-08T04:04:42.461Z updated_at: 2026-03-08T04:04:43.569Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 349 locale: en source: 13F Insight --- # Jack Schuler Kept Buying QuidelOrtho Below $12 as the Diagnostics Story Was Still Being Rebuilt > QuidelOrtho 10% owner Jack Schuler bought more stock in January 2026, extending a buy campaign that had already put several million dollars to work while the company remained in rebuild mode. Jack Schuler, a 10% owner of QuidelOrtho, bought roughly $2.1M of stock across January 22 to January 26, 2026. That January burst followed earlier 2025 accumulation and stands out because it came while the diagnostics company was still working through a credibility reset rather than celebrating a full turnaround. What Happened DateInsiderCodeSharesPriceValue 2026-01-26Jack SchulerP20,000$11.80$0.24M 2026-01-23Jack SchulerP80,000$11.81$0.94M 2026-01-22Jack SchulerP82,465$10.96$0.90M 2025-11-24Joseph BuskyP4,770$26.06$0.12M Open-market buying is more informative than exercise-related noise, especially in a diagnostics name that had already lost a lot of investor trust. Schuler's purchases signal willingness to add risk while the story still needed proof, not after the easy rerating had already happened. Why It Matters The setup matters as much as the dollars. Buyers stepping in below $12 are effectively saying the downside narrative had gone too far. That does not make them automatically right, but it does make the signal stronger than a routine executive option event. This is exactly the distinction covered in our open-market buys versus exercises framework. QuidelOrtho also sits in a crowded diagnostics landscape next to names like Thermo Fisher, Danaher, Abbott, Illumina, and Quest Diagnostics. That makes insider buying more notable because the buyers had no shortage of alternative places to allocate capital. What This Is Not This is not a proof-of-turnaround article. It is an article about incentive alignment and timing. Schuler bought when the market still needed convincing. The read-through is that he saw enough asymmetry to keep adding even before sentiment was repaired. Key Facts Primary buyerJack Schuler, 10% owner January 2026 buy valueAbout $2.1M Supporting insider contextCFO Joseph Busky had also bought in late 2025 Signal typeOpen-market accumulation, not a mechanical option exercise What to Watch QuidelOrtho execution: whether operating progress starts to validate the below-$12 buying window. Additional insider activity: whether Schuler keeps buying or the rest of the insider group joins him. Peer relative performance: how QuidelOrtho trades versus Thermo Fisher, Danaher, and Abbott. Market skepticism: whether the stock still trades as a restructuring story instead of as a recovered diagnostics franchise. Ownership structure: whether the 10% owner remains consistently additive in future Form 4 filings. --- Source: 13F Insight — https://13finsight.com/news/jack-schuler-kept-buying-quidelortho-below-12-while-the-stock-was-still-rebuilding Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-03-08T04:04:43.569Z